Brokerage Firm Rating Update on Sequenom (SQNM)

Sequenom (SQNM) has an average broker rating of 3, which is interpreted as a Hold, as rated by 4 equity analysts. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Sequenom (SQNM) : Average target price received by Sequenom (SQNM) is $1.35 with an expected standard deviation of $0.91. The most aggressive target on the stock is $2, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.


Company shares have received an average consensus rating of Hold for the current week

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.